Cargando…
Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
PURPOSE: To evaluate the initial efficacy and safety of intravitreal faricimab in eyes previously treated for neovascular age-related macular degeneration (nARMD). PATIENTS AND METHODS: A retrospective review of all patients with nARMD previously treated with anti-vascular endothelial growth factor...
Autores principales: | Leung, Ella H, Oh, Daniel J, Alderson, Shannon E, Bracy, Joshlynn, McLeod, Mia, Perez, Litzi I, Bottini, Alexander, Chin Yee, David, Mukkamala, Krishna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167970/ https://www.ncbi.nlm.nih.gov/pubmed/37181079 http://dx.doi.org/10.2147/OPTH.S409822 |
Ejemplares similares
-
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023) -
Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022) -
Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
por: Kikuchi, Yusuke, et al.
Publicado: (2023) -
Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022) -
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
por: Khanani, Arshad M., et al.
Publicado: (2023)